Prepared By
Douglas Thamm, VMD, DACVIM (Oncology)
The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma
William P. Katt, Cheryl E. Balkman, Scott D. Butler, Michael Byron, Patrick C. Carney, Amy B. Todd-Donato, Matthew E. Drozd, Gerald E. Duhamel, Jacquelyn M. Evans, Nadine Fiani, Jordan C. Ford, Jennifer K. Grenier, Jessica J. Hayward, Kristiina Heikinheimo, Kelly R. Hume, Elizabeth S. Moore, Rishi Puri, Skylar R. Sylvester, Sydney L. Warshaw, Suzin M. Webb, Andrew C. White, Alexandra L. Wright, Richard A. Cerione & Santiago Peralta
Published: 27 February 2025
https://www.nature.com/articles/s41598-025-90574-3
Background
Oral squamous cell carcinoma (OSCC) is relatively frequent in dogs, accounting for about 30% of oral tumors. Behavior is variable depending on location and histologic features, but both local recurrence and metastasis can be concerns in individual cases, and novel medical therapies have the potential to be useful. The Authors previously demonstrated that a large majority of canine OSCC appear to have activation of the RAS-RAF-MEK-ERK signaling pathway, which is critical for sustained cell proliferation. A subset of canine OSCC appear to have activating mutations in BRAF identical to those found in human melanoma and canine urothelial carcinoma. Small molecule inhibitors of MEK signaling are useful in human BRAF-mutant tumors and potentially other tumors with sustained RAS-RAF-MEK-ERK signaling, and the clinical inhibitor trametinib has demonstrated antiproliferative activity in vitro in several canine malignancies. The Authors sought to establish a series of canine OSCC patient derived xenografts (PDX) and cell lines, and evaluate the antitumor effects of trametinib in these models as well as in a small cohort of dogs with OSCC.
Study Design
This was a combination of in vitro assessment in cell lines and PDX models and a pilot clinical trial in dogs.
Animals
NSG mice and dogs with spontaneous OSCC were studied.
Methods
With owner informed consent, primary tumors surgically excised from canine OSCC patients were minced and implanted into NSG mice, then serially passaged into additional mice. At multiple in vivo passages, the resulting tumors were disaggregated and attempts were made to propagate the cells in 2-dimensional culture.
Primary tumors, PDX tumors and cell lines were compared to each other via histopathology/immunohistochemistry and SNP genotyping. Cell lines were treated with various anticancer agents including trametinib, and resultant IC50s compared to data from the NCI60 cell line panel. Efficacy of trametinib was assessed in one of the PDXs, and in 4 dogs with spontaneous OSCC.
Results
PDXs were successfully established from multiple primary OSCC tumors, and there was generally good correlation in genotype between primary tumor, PDX and cell line. There was very long latency between tumor implantation and growth of a palpable tumor in many oft he PDXs, which would limit their utility for investigations. However, one PDX was serially passaged in mice, and then the subsequenly derived cell line was serially passaged resulting in a model with rapid tumor take and progression.
The drugs docetaxel, 5-FU, cetuximab, carmustine, temozolomide, trametinib and dabrafenib were assessed for antiproliferative effects against the OSCC cell lines. Most cells were very sensitive to trametinib, with IC50's lower than the average IC50 in the NCI60 human cell line panel. Trametinib induced significant growth inhibition in a canine OSCC xenograft, although tumor regression was not observed.
In the pilot canine OSCC clinical trial, some tumor shrinkage was observed in 2 of 4 dogs treated with trametinib at a dose of 0.015-0.02 mg/kg daily.
Important Findings
The Authors did a very thorough job developing and validating their PDXs and resultant cell lines. While PDXs are commonly used in human oncology, they are somewhat in their infancy in veterinary oncology and the information here provides a good benchmark for validation approaches in subsequent studies.
The fact that trametinib induced antiproliferative effects in vitro and in vivo is useful, but it is always important to keep in mind whether drug concentrations capable of exerting these effects are achievable in patients. In this case, the drug concentrations they used in vitro are clinically achievable, and the fact that some modicum of antitumor activity was observed supports the potential clinical relevance of their findings.
Study Limitations
Only short term responses to trametinib were assessed - outcomes beyond 56 days were not reported. Tumor measurements were the only clinical outcomes reported. The results would have been strengthened if pharmacokinetic and pharmacodynamic assessments could have been made to bolster the case that inhibition of MEK signaling was observed in post-treatment biopsy samples.
Journal Reviewer Comments
This is the first published information demonstrating objective responses to trametinib in any canine cancer, which suggests that concentrations of trametinib capable of antitumor effects are achievable in dogs with acceptable toxicity. More complete assessment of the efficacy of this drug in OSCC, including pharmacokinetic/pharmacodynamic assessments and more long term follow-up, is eagerly awaited.
It's important to note that formulation of trametinib is critical, if it is being obtained through compounding pharmacies rather than obtaining USP material. Specifically, trametinib must be sulfated in order to be orally bioavailable (see Wei et al Front Vet Sci 2022).
Overall, this is an interesting and useful contribution to the literature, and trametinib may gain a role in our therapeutic arsenal for this disease. However, I would encourage the surgeons not to put down their scalpels just yet - complete excision is going to remain the first line of therapy for canine OSCC for the foreseeable future.

Leave a Reply
Want to join the discussion?Feel free to contribute!